T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours-Reference-Cited by-同舟云学术

T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

Published:2021-06-03 Issue:11 Volume:5 Page:1246-1260
ISSN:2157-846X
Container-title:Nature Biomedical Engineering
language:en
Short-container-title:Nat Biomed Eng

Author:

Lesch Stefanie^ORCID,Blumenberg Viktoria^ORCID,Stoiber Stefan,Gottschlich Adrian^ORCID,Ogonek Justyna,Cadilha Bruno L.^ORCID,Dantes Zahra,Rataj Felicitas,Dorman Klara,Lutz Johannes,Karches Clara H.,Heise Constanze,Kurzay Mathias,Larimer Benjamin M.^ORCID,Grassmann Simon,Rapp Moritz,Nottebrock Alessia,Kruger Stephan,Tokarew Nicholas,Metzger Philipp^ORCID,Hoerth Christine,Benmebarek Mohamed-Reda^ORCID,Dhoqina Dario,Grünmeier Ruth,Seifert Matthias^ORCID,Oener Arman,Umut Öykü,Joaquina Sandy,Vimeux Lene,Tran Thi,Hank Thomas^ORCID,Baba Taisuke,Huynh Duc,Megens Remco T. A.^ORCID,Janssen Klaus-Peter^ORCID,Jastroch Martin,Lamp Daniel,Ruehland Svenja,Di Pilato Mauro,Pruessmann Jasper N.,Thomas Moritz,Marr Carsten,Ormanns Steffen,Reischer Anna,Hristov Michael,Tartour Eric^ORCID,Donnadieu Emmanuel,Rothenfusser Simon^ORCID,Duewell Peter,König Lars M.^ORCID,Schnurr Max,Subklewe Marion,Liss Andrew S.^ORCID,Halama Niels^ORCID,Reichert Maximilian,Mempel Thorsten R.,Endres Stefan^ORCID,Kobold Sebastian^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Computer Science Applications,Biomedical Engineering,Medicine (miscellaneous),Bioengineering,Biotechnology

Link

https://www.nature.com/articles/s41551-021-00737-6.pdf

Reference86 articles.

1. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).

2. Kobold, S. et al. Immunotherapy in tumors. Dtsch. Ärztebl. Int. 112, 809–815 (2015).

3. Sheridan, C. First approval in sight for Novartis’ CAR-T therapy after panel vote. Nat. Biotechnol. 35, 691–693 (2017).

4. Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2)—specific chimeric antigen recpetor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688–1696 (2015).

5. Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights;Frontiers in Immunology;2024-09-05

2. Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides;Human Vaccines & Immunotherapeutics;2024-08-28

3. Strategies for Improving CAR T Cell Persistence in Solid Tumors;Cancers;2024-08-16

4. Cracking the Codes behind Cancer Cells’ Immune Evasion;International Journal of Molecular Sciences;2024-08-15

5. Chimäre Antigenrezeptor-T-Zellen – Die Evolution zellulärer Immuntherapie von malignen zu nicht-malignen Erkrankungen;Aktuelle Rheumatologie;2024-08